Last reviewed · How we verify
Celsentri®
Celsentri is a CCR5 antagonist that blocks the CCR5 co-receptor on CD4+ T cells, preventing HIV entry and infection.
Celsentri is a CCR5 antagonist that blocks the CCR5 co-receptor on CD4+ T cells, preventing HIV entry and infection. Used for HIV-1 infection in treatment-experienced patients with CCR5-tropic virus.
At a glance
| Generic name | Celsentri® |
|---|---|
| Sponsor | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer |
| Drug class | CCR5 antagonist |
| Target | CCR5 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Celsentri (maraviroc) binds to the CCR5 chemokine receptor on the surface of CD4+ T cells and blocks the attachment and entry of CCR5-tropic HIV strains. By selectively antagonizing this co-receptor, the drug prevents the virus from infecting cells while preserving the immune function of the targeted lymphocytes. This mechanism is distinct from reverse transcriptase or protease inhibitors and represents an entry/fusion inhibitor class.
Approved indications
- HIV-1 infection in treatment-experienced patients with CCR5-tropic virus
Common side effects
- Upper respiratory tract infection
- Cough
- Pyrexia
- Rash
- Abdominal pain
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
- The Role of Home Packs of HIV PEPSE in High Risk Individuals (PHASE4)
- Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF (PHASE3)
- Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)
- Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Celsentri® CI brief — competitive landscape report
- Celsentri® updates RSS · CI watch RSS
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer portfolio CI